Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Trinity Biotech also is a provider of raw materials to the life sciences and research industries globally. Trinity Biotech markets its portfolio of almost 850 products to customers in approximately 100 countries around the world. The primary market for Trinity Biotech's diagnostic products is the Americas (which consists principally of North America and South America). Its products are classified as point-of-care, emergency medicine, clinical laboratory and blood bank screening. The Company markets products under Uni-Gold, Recombigen, Meritas, Captia, MicroTrak, Bartels, MarDx, MarBlot, Premier, Ultra2, ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ.
|Headquarters||IDA Business Park|
BRAY, Ireland 18
|Executive Chairman of the Board||Ronan O'Caoimh|
|Chief Financial Officer, Secretary||Kevin Tansley|
|Chief Operating Officer, Executive Director||Rory Nealon|
|Chief Scientific Officer, and Vice President Cardiac||Eric Brouwer|
|Executive Director||James Walsh|
|Shares Out.||23.7M||Book Value||$8.52|
|Annual Dividend Rate||0.22 USD||Price/Sales (TTM)||4.1|
|Ex-Div Date||6/5/15||P/Cash Flow (TTM)||--|
|Pay Date||7/1/15||Operating Margin||17.00%|
*GAAP = prior to non-GAAP analyst adjusted earnings.